Nordic Nanovector To Present Clinical Data From Phase I/II Trial On Betalutin™ At Upcoming American Society of Hematology Meeting

OSLO, Norway--(BUSINESS WIRE)--Nordic Nanovector ASA (“Nordic Nanovector” or “the Company”) today announced that data from Betalutin’s Phase I/II trial will be presented in a poster session at the American Society of Hematology (ASH) 2014 Annual Meeting (December 6-9) in San Francisco. The poster reports the preliminary efficacy and safety data of patients with relapsed NHL enrolled in a 3+3 dose escalation Phase I study testing 3 different dose levels of Betalutin™. “We are looking forward to presenting the clinical results for Betalutin, the first radioimmunotherapeutic solution targeting CD-37 receptors on lymphoma cells that, thanks to its unique multi-cell kill approach, can deliver a robust clinical activity with a predictable safety profile,“ said Nordic Nanovector CEO, Luigi Costa.

Help employers find you! Check out all the jobs and post your resume.